The tablet formulation is based on a novel natural biodegradable polymer derived from milk protein concentrate (MPC) in combination with hydrophilic matrix made of hypromellose, associated with active substance, and specially designed to allow rapid bioadhesion.

The tablet is applied to the gingival mucosa at the canine fossa.

Thanks to that bioadhesion, the homogenously dispersed API within the tablet is delivered both rapidly and extendedly at the site of disease itself, enabling continuous therapeutic pressure on the pathogenic agent or causal organism.

This innovative and advanced drug-delivery system enables the extended release of API in the saliva and in the mucosal tissue.